tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
PremiumRatingsBuy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
2M ago
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
Premium
Company Announcements
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
2M ago
Marker Therapeutics reports evidence from Phase 1 APOLLO study
Premium
The Fly
Marker Therapeutics reports evidence from Phase 1 APOLLO study
2M ago
Marker Therapeutics initiated with a Buy at Canaccord
PremiumThe FlyMarker Therapeutics initiated with a Buy at Canaccord
5M ago
Marker Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Marker Therapeutics initiated with a Buy at Canaccord
5M ago
Marker Therapeutics Grants Stock Options to Directors
Premium
Company Announcements
Marker Therapeutics Grants Stock Options to Directors
5M ago
Marker Therapeutics provides update on MT-601 patients
PremiumThe FlyMarker Therapeutics provides update on MT-601 patients
7M ago
Marker Therapeutics awarded $9.5M grant from CPRIT
Premium
The Fly
Marker Therapeutics awarded $9.5M grant from CPRIT
7M ago
Marker Therapeutics files $300M mixed securities shelf
Premium
The Fly
Marker Therapeutics files $300M mixed securities shelf
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100